Objectives
Risk factors of breast carcinoma.
Etiopathogenesis.
Types: In situ / Invasive.
Well-Established Influences
1. Geographic factors 2. Age 3. Family history Varies in different areas Increases after age 30yr
1.2-3.0
3.1 8.5-9.0 1.5 4.0-5.4
Well-Established Influences
4. Menstrual history i. Age at menarche <12yr 1.3
1.5-2.0
2.0-3.0
3.0
Well-Established Influences
6. Benign breast disease Proliferative disease without atypia Proliferative disease with atypical hyperplasia Lobular carcinoma in situ 1.6 >2.0 6.9-12.0
Pathogenesis
(1) Genetic changes,
A large number of genes including the estrogen receptor may be inactivated by promoter hypermethylation.
Multiple acquired genetic alterations are involved in the sequential transformation of a normal epithelial cell into a CANCEROUS CELL.
Genetics
Gene expression profiling can stratify breast cancer into five subtypes: 1. Luminal A (estrogen receptor positive), 2. Luminal B (estrogen receptor positive),
Increased exposure to estrogen peaks during the menstrual cycle (long duration of reproductive life, nulliparity, and late age at birth of first child), Functioning ovarian tumors that elaborate estrogens,
Exogenous estrogens.
Invasive carcinoma
Ductal carcinoma (No Special Type)
Lobular carcinoma
Tubular carcinoma
Mucinous carcinoma Medullary carcinoma Papillary carcinoma Metaplastic carcinoma
CARCINOMA IN SITU
1. DCIS (INTRADUCTAL CARCINOMA in situ):
Neoplastic population of cells limited to ducts and lobules by the basement membrane. 15%-30% in well-screened population. Mammographic calcification. Vague palpable mass / nipple discharge / incidental.
DCIS - MICROSCOPY
Architectural subtypes
A. Comedocarcinoma
B. Noncomedocarcinoma
1. Solid 2. Cribriform 3. Papillary 4. Micropapillary
A. COMEDOCARCINOMA
Solid sheets of pleomorphic cells with high grade nuclei and central necrosis.
Periductal fibrosis, chronic inflammation. Necrotic cell membranes calcify microcalcifications (mammography).
Comedo DCIS fills several adjacent ducts and is characterized by large central zones of necrosis with calcified debris.
B.NONCOMEDO DCIS
Monomorphic population of cells.
Nuclear grade low to high.
B.2.CRIBRIFORM DCIS
Intraepithelial spaces:
- even distribution.
-
B.2.CRIBRIFORM DCIS
B.3.PAPILLARY DCIS
Papillary growths into spaces, lined by a monomorphic population of tall columnar cells.
B.3.PAPILLARY DCIS
B.4. MICROPAPILLARY
Papillae - narrow base, solid, no fibrovascular core.
Bulbous protrusions.
Calcifications.
Paget cells : extend from DCIS within the ductal system into nipple skin without crossing basement membrane. Disrupt normal epithelial barrier extracellular fluid to seep out into the nipple surface.
50 to 60% of Paget disease have palpable mass with underlying invasive carcinoma.
Paget disease of the nipple. DCIS arising within the ductal system of the breast can extend up the lactiferous ducts into nipple skin without crossing the basement membrane. ET DISEASE OF NIPPLE
TREATMENT
Mastectomy DCIS curative in over 95%.
Lobular carcinoma in situ. A monomorphic population of small, rounded, loosely cohesive cells fills and expands the acini of a lobule.
Desmoplastic stroma.
Well-differentiated invasive carcinoma of no special type. Well-formed tubules and nests of cells with small monomorphic nuclei invade into the stroma with a surrounding desmoplastic response.
Poorly differentiated invasive carcinoma of no special type. Ragged sheets of pleomorphic cells without tubule formation infiltrate into the adjacent stroma.
Metastasis:
3.MEDULLARY CARCINOMA
Well circumscribed mass.
3.MEDULLARY CARCINOMA
Gross:
Wellcircumscribed.
3.MEDULLARY CARCINOMA
Microscopy:
Solid sheets, large cells with vesicular nuclei, prominent nucleoli, frequent mitosis. Lymphoplasmacytic infiltrate. Pushing borders. All Med. Ca.: poorly differentiated. No lymphatic / vascular invasion.
Medullary carcinoma. The cells are highly pleomorphic with frequent mitoses and grow as sheets of cohesive cells. A lymphoplasmacytic infiltrate is prominent.
Older patients.
Slow growth.
Gross Extremely soft. Sharply circumscribed Pale grey blue gelatinous appearance.
Mucinous (colloid) carcinoma. The tumor cells are present as small clusters within large pools of mucin. The borders are typically well circumscribed, and these cancers often mimic benign masses.
5. TUBULAR CARCINOMA
2% - before, now 10%.
5. TUBULAR CARCINOMA
Microscopy:
Well formed tubules, no myoepithelial cells.
Microscopy
7.METAPLASTIC CARCINOMA
Rare (<1%)
Conventional adenocarcinoma
with
Chondroid stroma
Squamous cell carcinoma
Carcinomas < 1 cm have an excellent prognosis in the absence of lymph node metastases. 90% survival without treatment.
Sentinel nodes: Predictor of status of remaining nodes. Spare complete axillary node dissection if negative.
b. Progesterone receptors
c. HER2/neu
2. Tumor Grade Bloom Richardson Grading System 10 yr survival Gr1 60%, Gr2 15%, Gr 3 10%
THERAPEUTIC APPRAOACHES
Current:
Combination of surgery & postoperative radiation & systemic control hormonal or chemotherapy or both.
Newer strategies:
Summary
Carcinoma of breast: In situ / Invasive. In situ: limited by basement membrane. Invasive: Invasion into the stroma. The normal breast is maintained by a complex set of interactions among luminal cells, myoeithelial cells, the basement membrane, and the stromal cells. Multiple acquired genetic alterations are involved in the sequential transformation of a normal epithelial cell into a cancerous cell.
Risk factors: delayed child bearing, long duration between menarche and menopause, atypical proliferative lesions, and
family history of breast cancer in a first-degree relative, particularly if the disease was multifocal or premenopausal.
Only 5% to 10% of all breast cancers are related to inherited mutations; The majority are in the BRCA1 and BRCA2 genes, less commonly in p53, PTEN or ATM genes.
proliferation rate,
estrogen receptor status, aneuploidy, and overexpression of HER2/NEU.
"When you make a mistake, don't look back at it long. Take the reason into your mind, and then look forward. Mistakes are lessons of wisdom. The past cannot be changed. The future is yet in your power."
Phyllis Bottome 1884-1963, Novelist and Lecturer